Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, announces the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat patients living with rare and life-threatening diseases.
To accelerate innovation, in March 2021 Yposkesi welcomed SK Pharmteco, a global CDMO player, as a new majority equity shareholder in its company. Backed by SK Pharmteco, Yposkesi is investing €58M (approx. $71M) in the new 5,000m² site, making it one of the largest ATMP facilities in Europe. Project SKY will create approximately 80 new jobs by 2023.
With this new state-of-the-art facility, designed for European and American GMP compliance, Yposkesi will double its production surface to 10,000m². This new resource equips it to address the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.
Yposkesi is proud and excited to embark full speed on this new phase in our development. SKY is the culmination of our industrial strategy, guaranteeing clients a range of quality services from early clinical drug development through all phases to the manufacture of large-scale commercial batches of ATMPs, – said Alain Lamproye, executive chairman of Yposkesi. – This project will also showcase our outstanding technological know-how in bioproduction for gene therapy drugs.
Yposkesi contracted CBI, a subsidiary of Vinci Construction France, to build the facility; with Pharmaplan, an engineering service for the pharmaceutical industry, as the prime contractor.
The new building will house two additional production lines with several 1000L scale bioreactors. This allows Yposkesi to enhance its competitive offering through its ability to support client projects from the early process development phases up to large scale manufacturing of approved drugs.